Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Gutteridge
Eleanor
E
Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham, HG5 1PB, UK. Eleanor.Gutteridge@nottingham.ac.uk
Robertson
John F R
JF
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D055808:Drug Discovery; D004345:Drug Industry / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods
D066246:ErbB Receptors; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases